September 25, 2017 • Seattle, WA

Presage Biosciences Awarded Debut Grant from The Mark Foundation for Cancer Research to Support Immuno-Oncology Applications of CIVO™, an Intratumoral Microdosing Platform

The grant is aimed at advancing Presage’s next generation of intratumoral microdosing platform to assess immuno-oncology drug combinations.…

Learn More

September 05, 2017 • San Diego and Seattle

MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor

MEI Pharma, Inc (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that it has entered into a license agreement with Presage Biosciences, Inc. for voruciclib…

Learn More

June 01, 2017 • Cancer Res

Multidrug Analyses in Patients Distinguish Efficacious Cancer Agents Based on Both Tumor Cell Killing and Immunomodulation

Frazier JP, Bertout JA, Kerwin WS, Moreno-Gonzalez A, Casalini JR, Grenley MO, Beirne E, Watts KL, Keener A, Thirstrup DJ, Tretyak I, Ditzler SH, Tripp CD, Choy K, Gillings S, Breit MN, Meleo KA, Rizzo V, Herrera CL, Perry JA…

Learn More

September 01, 2016 • Magn Reson Med

Minimally invasive in tumor multidrug comparative analysis with contrast-enhanced MRI in mice

Kerwin WS, Tretyak I, Grenley MO, You S, Hatton BA, Moreno-Gonzalez A, Thirstrup DJ, Klinghoffer RA…

Learn More

June 30, 2016 • PLoS One

A Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In Vivo

Dey J, Kerwin WS, Grenley MO, Casalini JR, Tretyak I, Ditzler SH, Thirstrup DJ, Frazier JP, Pierce DW, Carleton M, Klinghoffer RA…

Learn More

June 23, 2016 • Seattle, WA

Presage Biosciences Appoints David Johnson to Board of Directors

Presage Biosciences, an oncology company that is developing a novel drug development platform to assess drugs and combinations directly in patient tumors, announced today the appointment of David Johnson to its board of…

Learn More

April 19, 2016 • Seattle, WA

Presage Biosciences Presents Data Demonstrating Tumor Growth Inhibition by Voruciclib and Proteasome Inhibitors Superior to Single Agents in Model of Triple Negative Breast Cancer

Presage Biosciences, an oncology company that is developing a novel drug development platform to assess drug combinations directly in patient tumors, will present preclinical data showing that the company’s clinical-stage…

Learn More

April 14, 2016 • Seattle, WA

Presage Biosciences Extends Research Collaboration with Takeda to Discover Novel Cancer Drug Combinations

Presage Biosciences, an oncology company that has established a novel drug development approach to assess drug combinations directly in-patient tumors, announced today that is has entered into a multi-year extension of its …

Learn More

March 18, 2016 • Vet Comp Oncol

Establishment and characterization of a canine soft tissue sarcoma patient-derived xenograft model

Frazier JP, Beirne E, Ditzler SH, Tretyak I, Casalini JR, Thirstrup DJ, Knoblaugh S, Ward JG, Tripp CD, Klinghoffer RA …

Learn More

January 11, 2016 • Seattle, WA

Presage Biosciences Appoints Oncology Experts to Newly Created Medical Advisory Panel

Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today the formation of a Medical…

Learn More

November 24, 2015 • Seattle, WA

Presage Biosciences In-Licenses Clinical Stage Drug Program

Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today that it has in-licensed …

Learn More

November 24, 2015 • Seattle, WA

Presage Biosciences Appoints Two New Directors

Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today the appointment of Tachi…

Learn More

October 01, 2015 • Cancer Chemother Pharmacol

Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration

Chen N, Brachmann C, Liu X, Pierce DW, Dey J, Kerwin WS, Li Y, Zhou S, Hou S, Carleton M, Klinghoffer RA, Palmisano M, Chopra R…

Learn More

August 20, 2015 • Seattle, WA

Presage Biosciences Receives Strategic Investment from Takeda

Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, today announced that it has secured a …

Learn More

June 10, 2015 • Mol Cell Oncol

Predicting responses to chemotherapy in the context that matters – the patient

Moreno-Gonzalez A, Olson JM, Klinghoffer RA…

Learn More

June 01, 2015 • Nat Rev Cancer

Drug delivery: Get in there

Villanueva MT …

Learn More

April 22, 2015 • Seattle, WA

Study finds that microinjection platform enables assessment of multiple cancer drugs directly in tumors, predicts systemic response

A newly developed technology for simultaneously comparing response to multiple cancer drugs or combinations while a tumor is still in a patient’s body has been shown to accurately predict systemic response to the drugs, …

Learn More

April 22, 2015 • Sci Transl Med

A technology platform to assess multiple cancer agents simultaneously within a patient’s tumor

Klinghoffer RA, Bahrami SB, Hatton BA, Frazier JP, Moreno-Gonzalez A, Strand AD, Kerwin WS3, Casalini JR, Thirstrup DJ, You S, Morris SM, Watts KL, Veiseh M, Grenley MO, Tretyak I, Dey J, Carleton M, Beirne E, Pedro KD... …

Learn More

April 22, 2015 • Sci Transl Med

Drug testing in the patient: toward personalized cancer treatment

Coombes RC…

Learn More

March 20, 2015 • Seattle, WA

Presage Biosciences Granted Sixth U.S. Patent for CIVO™ Arrayed Microinjection Technology for Comparing Multiple Drugs in a Single Living Tumor

Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today that the U.S. Patent and Trade…

Learn More

March 16, 2015 • Seattle, WA

Presage Biosciences Appoints Brad Margus to Board of Directors

Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today the appointment of Brad Margus…

Learn More

November 12, 2014 • Seattle, WA

Presage Biosciences Expands Collaboration with Takeda for CIVO™ Technology to Assess Cancer Drugs Directly in Solid Tumors

Presage Biosciences, an oncology company developing a radical new testing approach that incorporates human data much earlier in drug development and clinical trials, announced today that it has expanded its cancer research …

Learn More

October 21, 2014 • Seattle, WA

Presage Biosciences Granted Fifth U.S. Patent for CIVO™ Arrayed Microinjection Technology for Comparing Multiple Drugs in a Single Living Tumor

Presage Biosciences, an oncology company developing a radical new testing approach that incorporates human efficacy data much earlier in drug development and clinical trials, announced today that the U.S. Patent and Trademark…

Learn More

September 04, 2014 • KUOW

One Doctor Makes The Case For Human Trials

Marcie Sillman talks with Fred Hutchinson cancer researcher Dr. Jim Olson about the development of a new human drug-testing model. …

Learn More

April 08, 2014 • Seattle, WA

Presage Biosciences Presents Proof-of-Concept Data for CIVO™ Preclinical Assessment Platform at AACR 2014 Annual Meeting

Presage Biosciences, a biotechnology company focused on bringing the earliest human efficacy data possible into cancer drug development, presented preclinical data showing that microinjection of several standard-of-care …

Learn More

September 24, 2013 • Seattle, WA

Presage Biosciences Named a “Fierce 15” Biotech Company of 2013 by FierceBiotech

Presage Biosciences, a leader in precision oncology, has been named by FierceBiotech as one of 2013’s Fierce 15 biotechs, designating it as one of the most promising private biotechnology companies in the industry. This is…

Learn More

September 24, 2013 • FierceBiotech

Presage Biosciences – 2013 Fierce 15

Learn More

September 13, 2013 • National Public Radio (NPR) Morning Edition

Treating Kids’ Cancer With Science And A Pocket Full Of Hope

NPR’s Joe Palca visits with Jim Olson in a story that describes Dr. Olson’s inspiration and hope for cancer treatment.…

Learn More

April 19, 2013 • Seattle, WA

Presage Biosciences Announces First Patient in Clinical Trial of CIVO™ Precision Oncology

Presage Biosciences, a leader in precision oncology, today announced the initiation of a clinical trial and the first patient use of CIVO™, the company’s precision oncology platform designed to improve treatment decisions for…

Learn More

March 05, 2013 • Seattle, WA

Presage Biosciences Announces Strategic Research Alliance with Celgene Corporation

Presage Biosciences, a leader in discovering effective cancer drug combinations, today announced that it has entered into a strategic collaboration agreement with Celgene Corporation under which Presage and Celgene will take …

Learn More

January 16, 2013 • MIT Technology Review

Device Tests Drugs on a Tumor That’s Still in the Body

Presage’s device would allow oncologists to test potentially harmful compounds in tiny amounts before giving patients a full dose.…

Learn More

May 07, 2012 • BioCentury

Comparing combos quickly

Millennium Pharmaceuticals Inc. is using an in vivo screening platform from Presage Biosciences Inc. to speed up its preclinical characterization of cancer combination therapies. The platform enables simultaneous comparison …

Learn More

April 06, 2012 • xconomy.com

Presage Looks to Help Millennium Pick Cancer Drug Winners Early

Seattle-based Presage Biosciences, a spinoff from the Fred Hutchinson Cancer Research Center, is looking to help cancer drugmakers separate the winning compounds from the losers early in development, and now it’s found a …

Learn More

April 06, 2012 • Mass High Tech

Millennium gets use of Presage drug combo technology

Millennium: The Takeda Oncology Company has entered into a cancer research agreement with Presage Biosciences of Seattle, Wash., that gives the Cambridge biopharmaceutical company access to Presage’s technology for non-clinic…

Learn More

April 06, 2012 • Science Business

Presage Biosciences, Millennium to Partner on Cancer Drugs

Presage Biosciences, a biotechnology company in Seattle, and Millenium, a division of Takeda Pharmaceuticals in Cambridge, Massachusetts, say the two companies will collaborate on the development of new cancer therapies. …

Learn More

April 05, 2012 • Seattle, WA

Presage Biosciences and Millennium Pharmaceuticals Enter Into Cancer Research Agreement

Presage Biosciences, a leader in identifying clinically viable oncology drug combinations, today announced that it has entered into a cancer research agreement with Millennium: The Takeda Oncology Company. The research agreem…

Learn More

December 15, 2011 • Seattle, WA

Presage Biosciences Appoints Jim Towne as CEO

Presage Biosciences, a privately held biotechnology company that works with oncology-focused pharmaceutical companies through strategic alliances using its patented three-dimensional in vivo drug analysis platform, announced …

Learn More